Mast Cell Therapy for Sickel Cell Anaemia

Pooja Panwar, Vivek Daniel, Kratika Daniel, Sarika Sharma
2015 International Journal of Pharmaceutical & Biological Archives   unpublished
Some sickle cell anaemia (SCA) patients suffer significantly worse phenotypes than others. Causes of such disparities are incompletely understood. Comorbid chronic inflammation likely is a factor. Recently, mast cell (MC) activation (creating an inflammatory state) was found to be a significant factor in sickle pathobiology and pain in a murine SCA model. Also, a new realm of relatively non cytoproliferative MC disease termed MC activation syndrome (MCAS) has been identified recently. MCAS has
more » ... ot previously been described in SCA. Some SCA patients experience pain patterns and other morbidities more congruent with MCAS than traditional SCA pathobiology (eg, vasoocclusion). Presented here are 32 poor-phenotype SCA patients who met MCAS diagnostic criteria; all improved with MCAS-targeted therapy. As hydroxyurea benefits some MCAS patients (particularly SCA-like pain), its benefit in SCA may be partly attributable to treatment of unrecognized MCAS. Further study will better characterize MCAS in SCA and identify optimal therapy.